The emergence of the CGRP‐monoclonal antibodies, which are the first of a class of migraine prophylactics designed to target specific known mechanisms involved in a migraine attack (the trigeminal pain system), presents a case for a detailed observation of a possible modification of migraine during treatment. This evidence concerns the gene CALCA and migraine disorder.